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Abstract
Background:Hybrid coronary revascularization (HCR) combining minimally invasive grafting of the left internal mammary artery to
the left anterior descending artery with percutaneous coronary intervention has become a viable option for treating coronary artery
disease. The aim of this meta-analysis was to compare HCR with conventional coronary artery bypass grafting (CABG) in a range of
clinical outcomes and hospital costs.
Methods: To identify potential studies, systematic searches were carried out in various databases. The key search terms included
“hybrid revascularization” AND “coronary artery bypass grafting” OR “HCR” OR “CABG.” This was followed by a meta-analysis
investigating the need for blood transfusion, hospital costs, ventilation time, hospital stay, cerebrovascular accident, myocardial
infarction, mortality, postoperative atrial fibrillation, renal failure, operation duration, and ICU stay.
Results: The requirement for blood transfusion was significantly lower for HCR: odds ratio 0.38 (95% confidence intervals [CIs]
0.31–0.46, P< .00001) as was the hospital stay: mean difference (MD) 1.48 days (95% CI, 2.61 to 0.36, P=0.01) and the
ventilation time: MD8.99hours (95% CI,15.85 to2.13, P= .01). On the contrary, hospital costs were more expensive for HCR:
MD $3970 (95% CI, 2570–5370, P< .00001). All other comparisons were insignificant.
Conclusions: In the short-term, HCR is as safe as conventional CABG and may offer certain benefits such as a lower requirement
for blood transfusion and shorter hospital stays. However, HCR is more expensive than conventional CABG.
Abbreviations: CABG = coronary artery bypass grafting, CI = confidence interval, CVA = cerebrovascular accident, DES = drug
eluting stent, HCR = hybrid coronary revascularization, ICU = intensive care unit, LAD = left anterior descending artery, LIMA = left
internal mammary artery, LITA = left internal thoracic artery, MACE/MACCE = major adverse cardiac events/major adverse cardiac
and cerebrovascular events, MD = mean difference, MI = myocardial infarction, OR = odds ratio, PCI = percutaneous coronary
intervention, POAF = postoperative atrial fibrillation, SVG = saphenous vein graft.
Keywords: blood transfusion, cardiac surgery, coronary artery disease, hospital costs, percutaneous coronary intervention1. Introduction
When comparing coronary artery bypass grafting (CABG) versus
percutaneous coronary intervention (PCI) for the treatment of
triple vessel or left main stem disease, the long-term results of
various randomized controlled trials support the use of CABG
(e.g., SYNTAX;[1] BARI;[2] FREEDOM).[3] One of the reasons
for CABG’s superiority is the gold standard approach of
bypassing the left anterior descending artery (LAD) using theEditor: Jacek Bil.
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left internal mammary artery (LIMA, also known as the left
internal thoracic artery [LITA]). Indeed, studies have reported
10-year patency rates from 95% to 98%.[4] An increasingly
attractive proposition is to operate using minimally invasive
techniques with a likely reduction in wound infection[5] and
shorter ICU stays.[6]
For lesions affecting non-LAD arteries, the saphenous vein
(SVG) can be the preferred conduit for CABG. However, SVGs
are not as robust as arterial conduits and an average failure rate
of 20% at 1 year and 40% to 50% at 10 to 15 years has been
reported.[4] In contrast in recent clinical trials the newer drug
eluting stents (DES) have been associated with a 3.9% restenosis
rate at 2 years and 5.9% target lesion revascularization rate at
4 years.[7] This favorable comparison combined with reduced
invasiveness supports the use of percutaneous coronary inter-
vention (PCI) in non LAD lesions.
The aim of hybrid coronary revascularization (HCR) is to
combineminimally invasive LITA to LADCABGwith PCI for the
other lesion(s). The first HCR was performed by Angelini et al in
1996.[8] The technique consisted of the combination of
percutaneous transluminal coronary angioplasty with anasto-
moses of LITA to LAD via a small left anterior thoracotomy. Six
patients underwent the procedure: 4 in a 2-stage process and 2 in
a simultaneous process. Afterward, all patients were reported to
be free from symptoms.[8] Increased interest in the approach
occurred with the advent of DES in the 2000s and between 2001
Reynolds and King Medicine (2018) 97:33 Medicineand 2016 twelve studies comparing HCR vesus conventional
CABGwere carried out. Possible benefits of HCR compared with
CABG included a lower requirement for blood transfusion[9–10]
and a shorter hospital stay.[11–12]
There have been 3 previous meta-analyses[13–15] comparing
CABG versus HCR; however, none of them include as many
studies as this one and none of them investigated the important
outcome, hospital cost. Therefore, the aim of this meta-analysis
was to provide a more comprehensive representation of all
available studies (14 included) and all available outcomes (11
included) to reach a conclusion about whether either approach is
clinically superior. The objective was to investigate whether there
was any superiority to treating adult patients with coronary
artery disease with HCR compared with conventional CABG.
The outcomes investigated were blood transfusion (number of
participants requiring); hospital cost; ventilation time; hospital
stay; cerebrovascular accident; myocardial infarction (MI);
mortality; postoperative atrial fibrillation (POAF); renal failure;
operation duration; and ICU stay.2. Methods
2.1. Ethical approval
This study involves pooling and synthesis of data from published
research. As such no humans or animals were utilized and
therefore no ethical approval was required.
2.2. Search strategy
To identify potential studies, systematic searches were carried
out using the following databases: EMBASE, PubMed, Web of
Science, and the Cochrane Central Registry of Controlled
Trials (CENTRAL). The search was supplemented by scanning
the reference lists of eligible studies. The search strategy
included the key concepts of “hybrid coronary revasculariza-
tion” AND “coronary artery bypass grafting” OR “HCR” OR
“CABG.” The details of the PubMed search are presented in
the supplementary files, http://links.lww.com/MD/C414. All
identified papers were assessed independently by 2 reviewers.
Searches of published papers were conducted up until
September 25, 2017.2.3. Types of studies to be included and excluded
All trials of patients undergoing HCR versus CABG were
included. There were no language restrictions. Animal studies
were excluded. Studies that did not have any of the desired
outcome measures were excluded. Incomplete data, or data from
an already included study, were excluded. Other treatment
modalities and interventions for coronary artery disease such as
percutaneous coronary intervention were only present in one of
the included studies, where HCR, CABG, and PCI were
compared with one another; in this case, the data for CABG
and HCR were extracted and the PCI sample excluded.[16] Data
extraction was performed by AR with double checking by NK.2.4. Participants/population
This meta-analysis analyzed all trials of both male and female
adult (≥18 years) patients with coronary artery disease who were
undergoing myocardial reperfusion using either HCR or
conventional CABG (treating multiple sites of atherosclerosis
with individual grafts).2
2.5. Intervention(s), exposure(s)
This meta-analysis considered all trials where patients with stable
angina or acute coronary syndrome were exposed to either HCR
or conventional CABG. More specifically, all trials, where the
intervention of combining PCI with CABG for the treatment of
myocardial ischemia, were used.
2.6. Search results
Our initial search found 348 articles. Of these 323 studies were
excluded on the basis of title and abstract. This left 25 studies. Of
these studies we excluded 8 studies because they had no
comparator group; 1 study because it was a single case study; 1
study because it only reported long-term outcomes; and 1 study
because it reported HCR versus percutaneous coronary interven-
tion (Supplementary Figure S1, http://links.lww.com/MD/C414).
Fourteen studies were included in our analysis.[9–13,16,17–25]
2.7. Outcome(s)
The primary outcomes analyzedwere blood transfusion (number of
participants requiring); hospital cost; ventilation time; hospital stay;
cerebrovascular accident; MI; mortality; postoperative atrial
fibrillation (POAF); renal failure; operation duration; and ICU stay.
2.8. Risk of publication bias
Risk of publication bias was assessed using funnel plots.[26]
2.9. Quality of included studies
The Newcastle Ottawa Scale was used to assess study quality
(http://www.ohri.ca/programs/clinical_epidemiology/nosgen.
doc). The results are displayed in Supplementary Table S2, http://
links.lww.com/MD/C414.
2.10. Strategy for data synthesis
Odds ratios were calculated for dichotomous data using the
Mantel–Haenszel method. An odds ratio (OR) is a measure of
association between an exposure and an outcome. The OR
represents the odds that an outcome will occur given a particular
exposure, comparedwith the odds of the outcome occurring in the
absence of that exposure. Mean differences were calculated for
continuous data. Meta-analyses were completed for continuous
data by calculating the mean difference between intervention and
control groups from postintervention data only. It is an accepted
practice to only use postintervention data for meta-analysis, but
thismethodassumes that randomallocationof participants always
creates intervention groups matched at baseline for age, disease
severity, where necessary median and ranges were converted to
mean and standard deviation.[27] All analyses were conducted
using Revman 5.3 (Nordic Cochrane Centre, Denmark). Hetero-
geneitywas quantified using the I2 test,[28] where a high percentage
suggests significant heterogeneity and 0% no heterogeneity. In the
presence of high heterogeneity, we used a random-effects model,
otherwise a fixed-effects model was used. We used a 5% level of
significance and 95% confidence intervals (CIs); figures were
produced using Revman 5.3.
3. Results
The 14 studies (15 intervention groups) included in the analyses
had an aggregate of 4260 participants, 1350 of which had HCR
and 2910 had conventional CABG. Table 1 summarizes the
Table 1
Characteristics of included studies.
Study HCR approach
CABG
approach
n HCR
(CABG)
Age HCR
(CABG)
% Male
HCR (CABG) <30 d Outcome measures
Bachinsky et al (2012)
USA
Robotic-assisted LIMA and/
or RIMA takedown.
Anterior chest wall incision
Either BMS or DES
Off pump 25 (27) 63.2±10.5
(66.78±10.7)
80 (59) Blood transfusion
Hospital costs
Hospital stay
ICU stay
MI
Mortality
Operation time
Pain
Patient satisfaction
POAF
Stroke
Time to return to work\normal
Troponin
De Canniere et al (2001)
Belgium
Minimally invasive
LIMA to LAD
Either BMS or DES
On-pump 20 (20) 62±9
(63±13)
80 (75) Atrial fibrillation
Blood transfusion
Leg wound dehiscence
Mobility \ independence
Myocardial damage or infarction
Pericardial effusion
Pleural effusion
Stroke
Delhaye et al (2010)
France
LIMA to LAD, RIMA to non-
LAD DES
Left to surgeon’s
preference
18 (18) 62 (60) 77.8 (77.8) Blood transfusion
Hospital Stay
MI
Mortality
Gasior et al (2014)
France
LIMA to LAD MIDCAB/
EACAB DES
Left to surgeon’s
preference
98 (102) 63.1± (63.9±8.4) 79.6 (71.6) Blood transfusion
MI
Mortality
Halkos et al (2011)
USA
LIMA to LAD EACAB
DES
Off pump 147 (588) 64.3±12.8 (64.3±
12.5)
61.9 (71.4) Blood transfusion
Hospital stay
ICU stay
MI
Mortality
POAF
Renal failure
Stroke
Ventilation Time
Harskamp et al (2015)
USA
LIMA to LAD
EACAB
DES
Left to surgeon’s
preference
306 (918) 64.6±11.6 (64.8±
10.4)
70.3 (67.4) Access site
Blood transfusion
Chest tube drainage
Infection
MI
Mortality
Operation time
Renal failure
Stroke
Hu et al (2011)
China
LITA to LAD
MIDCAB
Not reported
Off pump 104 (104) 61.8±10.2 (62.4±
8.0)
99.3 (79.8) Blood transfusion
Hospital costs
Hospital stay
ICU stay
Infection
MI
Mortality
Operation time
POAF
Kon et al (2008)
USA
LITA to LAD anterior lateral
minithoracotomy
DES
Off pump 15 (30) 61±10
(65±10)
73 (63) Blood transfusion
Hospital stay
ICU stay
Intraoperative cost
MI
Mortality
Pain
Renal insufficiency
Stroke
Ventilation time
Leacche et al (2013)
USA
LIMA to LAD assumed
DES assumed
On-pump SYNTAX score <3267
(226)
SYNTAX score >3213
(75)
62 (63)
74 (62)
79 (75)
62 (83)
Blood transfusion
Hospital stay
Mortality
Operation time
PLCOS
POAF
Renal failure
Stroke
Reicher et al (2008)
USA
LIMA to LAD anterior lateral
small thoracotomy DES
Off pump 13 (26) 62±10
(64±10)
80 (83) Blood loss
Blood transfusion
Hospital stay
ICU stay
Mortality
Ventilation Time
(continued )
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Table 1
(continued).
Study HCR approach
CABG
approach
n HCR
(CABG)
Age HCR
(CABG)
% Male
HCR (CABG) <30 d Outcome measures
Shen et al (2013)
China
LIMA to LAD
Ministernotomy
Surgeon’s preference 141 (141) 62.0±9.9 (62.4±7.8) 88.7% (90.1%) Death
MI
Neurologic event repeat
revascularization
“Any MACCE”
Song et al (2016)
China
LIMA to LAD
MIDCAB
99.5% DES
Off pump 120 (240) 62.3±9.4
(62.8±8.4)
80.8 (79.6) Blood transfusion
Hospital stay
ICU stay
Ventilation time
Zhao et al (2001)
USA
LIMA to LAD
DES
Both 122 (254) (Median)
63 (63)
Blood transfusion
Chest tube drainage
CK:MB
Creatine
New renal failure
POAF
Revision for bleeding
Stroke
Deep sternal wound infection
Hospital stay
Intra-aortic balloon pump
Intrastent thrombosis
Mortality
New low cardiac output syndrome
Zhou et al
(2014)
China
LIMA to LAD MIDCAB
Not reported
Off pump 141 (141) 62±10.1
(63.2±8.5)
88.7 (89.4) Atelectasis
Blood transfusion
Hospital stay
ICU stay
Intraaortic balloon pump
Mortality
Myocardial damage
Operation time
POAF
Renal failure
Stroke
Ventilation time
BMS=bare metal stent, CABG= coronary artery bypass grafting, CK-MB= creatine kinase, muscle brain band, DES=drug eluting stent, EACAB-HCR=hybrid coronary revascularization, ICU= intensive care
unit, LAD= left anterior descending artery, LIMA= left internal mammary artery, LITA= left internal thoracic artery, MACCE=major adverse cardiac or cerebrovascular events, MI=myocardial infarction,
MIDCAB=minimally invasive coronary artery bypass surgery, PLCOS=postoperative low cardiac output syndrome, POAF=postoperative atrial fibrillation, RIMA= right internal mammary artery.
Reynolds and King Medicine (2018) 97:33 Medicinecharacteristics of the included studies. Supplementary Table S1,
http://links.lww.com/MD/C414 lists the excluded trials and
reasons for exclusion.3.1. Blood transfusion
Ten studies reported the incidence of blood transfusion. Overall,
22.8% of HCR patients received a blood transfusion compared
with 46.1% of the CABG group. The odds ratio (OR) for theFigure 1. Requirement f
4
pooled analysis was OR 0.38 (95% CI, 0.31–0.46, I =48%,
P< .00001; Fig. 1). The odds of requiring a blood transfusion
were significantly lower in the patients who underwent HCR
compared with the odds of those who underwent CABG.
3.2. Hospital costs (thousands of US dollars)
Four studies examined the hospital costs of each procedure in US
dollars, which was converted to thousands of US dollars, to allowor blood transfusion.
Figure 2. Hospital costs.
Reynolds and King Medicine (2018) 97:33 www.md-journal.comfor a more comprehensive forest plot. The mean difference (MD)
for the pooled analysis was 3.97 thousand US dollars (95% CI,
2.57–5.37, I2=34%, P< .00001; Fig. 2). The hospital cost for
CABG was significantly lower than for HCR.
3.3. Ventilation time
Five studies reported intubation (mechanical ventilation) time in
hours for both procedures. The MD for the pooled analysis was
8.99hours (95% CI, 15.85 to 2.13, I2=96%, P= .01;
Fig. 3). There was a longer duration of mechanical ventilation
after CABG compared with HCR.
3.4. Hospital stay (days)
Six studies examined the postoperative length of stay of patients
in days. The MD for the pooled analysis was 1.48 days (95%
CI, 2.61 to 0.36, I2=84%, P= .010; Fig. 4). There was a
significantly shorter length of postoperative stay in hospital after
the HCR procedure than after CABG.
3.5. Cerebrovascular accident
Eight studies (9 intervention groups) examined the incidence of
cerebrovascular accident (CVA). The incidence of CVA in theFigure 3. Vent
Figure 4. Ho
5
HCR group was 0.9% compared with 1.4% in the CABG
group. The OR for the pooled analysis was 0.72 (95% CI,
0.31–1.69, I2=0%, P= .45; Figure S2, http://links.lww.com/
MD/C414). There were equal odds for the incidence of CVA in
both groups.3.6. MI
Nine studies examined the incidence of both peri- and
postoperative MI in the 2 procedures. 3.2% of patients treated
with HCR suffered a MI compared with 2.6% of patients
undergoing CABG. The OR for the pooled analysis was 0.54
(95% CI, 0.28–1.02, I2=4%, P= .06; Figure S3, http://links.
lww.com/MD/C414). There was no significant difference in the
odds of having an MI in the HCR or CABG groups.3.7. Mortality
Twelve studies (13 intervention groups) investigated the
incidence of mortality in both procedures. The incidence of
mortality in the HCR group was 1.7% as opposed to the CABG
where the incidence was 1.8%. The OR for the pooled analysis
was 1.15 (95% CI, 0.69–1.92, I2=20%, P= .59; Figure S4,
http://links.lww.com/MD/C414). There was no significantilation time.
spital stay.
Reynolds and King Medicine (2018) 97:33 Medicinedifference in the odds of mortality in the HCR group compared
with the CABG group.3.8. Postoperative atrial fibrillation
Seven studies (8 intervention groups) examined the incidence of
postoperative Atrial Fibrillation (POAF). In the HCR group, the
incidence of POAF was 17%, compared with 19.2% in the
CABG group. The OR for the pooled analysis was 0.96 (95%CI,
0.74–1.24, I2=35%, P= .74; Figure S5, http://links.lww.com/
MD/C414). There was no difference in the odds of POAF
occurring in the HCR group compared with the CABG group.3.9. Renal failure
Five studies (6 intervention groups) reported the incidence of
renal failure. In the HCR group, there was a renal failure
incidence of 1.7%, compared with 2.6% in the CABG group. The
OR for the pooled analysis was 0.73 (95% CI, 0.39 to 1.36, I2=
0%, P= .32; Figure S6, http://links.lww.com/MD/C414). There
was no difference in the odds of renal failure happening in either
the HCR or CABG group.3.10. Operation time (minutes)
Four studies examined the operation times for both procedures.
The MD for the pooled analysis was 46.17 minutes (95% CI,
13.88 to 106.22, I2=98%, P= .13; Figure S7, http://links.lww.
com/MD/C414). There was no significant difference between the
operation time for HCR versus that for CABG.3.11. ICU stay (hours)
Seven studies examined the length of stay of patients in the
intensive care unit (hours) after their procedure. The MD for the
pooled analysis was40.85 hours (95%CI,85.63 to 3.94, I2=
99%, P= .07; Figure S8, http://links.lww.com/MD/C414). There
was no significant difference in the length of stay in ICU between
the 2 groups.3.12. Leave one out/sensitivity analysis
A sensitivity analysis was carried out on all the significant results.
In the cases of requirement for blood transfusion, hospital costs
and hospital stay leaving out any single study still left a significant
result. When Reicher et al[12] were omitted from the ventilation
time analysis, the P value became .05.3.13. Publication bias
The funnel plots for requirement for blood transfusion, incidence
of myocardial infarction and postoperative atrial fibrillation were
symmetrical. All other funnel plots were nonsymmetric.
3.14. Study quality
According to the Newcastle Otawa Scale, most of the studies
were of reasonable quality with scores ranging from 7∗ to 8∗ out
of a maximum attainable score of 9∗.4. Discussion
A combination of the LIMA to LAD coronary artery bypass with
percutaneous coronary intervention for other coronary lesions has6
become a viable option. The aim of this meta-analysis was to
investigate how this hybrid approach compared with conventional
CABG using a range of clinical outcomes and also investigating
hospital cost. The results showed that the requirement for blood
transfusion, hospital stay, and ventilation time significantly favored
HCR,whereas conventionalCABGwas cheaper in termsof hospital
costs andall other comparisonswere insignificant. This suggests that
HCRhas some advantages comparedwith conventionalCABG, but
conventional CABG is the cheaper option.
Accompanying PCI with dual antiplatelet therapy is standard
practice. Due to concerns about bleeding complications it can be
preferred to perform the LIMA to LAD surgery first and then
carry out PCI.[9] This indeed appeared to be the case as in almost
all of the included studies CABG was carried out first[9–12,16–
17,19–25] except when the non-LAD lesion was critical.[10] In the
majority of the included studies, surgery and PCI were carried out
on the same day.[9–12,16–17,21,23–25] In which case administration
of clopidogrel occurred soon after surgery had taken place. Yet in
spite of this, the requirement for blood transfusion was
consistently lower in the HCR group. This is consistent with
the findings of other meta-analyses.[13–15] The reason for this is
thought to be the less invasive and traumatic nature of the
minimally invasive techniques used for the LIMA to LAD surgery
compared with a full sternotomy used in conventional CABG.[21]
The subject of hospital costs is controversial and involves
trying to balance best patient outcomes with value for money. In
all of the studies that investigated costs these were higher for
HCR, although in Reicher et al[12] the difference was insignifi-
cant. The greater cost for HCR could mainly be due to the use of
radiographic instruments and stent implantation.[21] It has been
suggested that with increasing experience such costs may
decrease, particularly when combined with the shorter hospital
stay.[17] It should also be noted the time taken for the patient to
return to work was significantly shorter after HCR compared
with conventional CABG.[17]
The clinical outcomes: incidence of CVA, MI occurrence,
mortality, incidence of POAF, and incidence of renal failure were
all insignificant at<30 days. Not surprisingly, this correlated well
with those authors who measured MACE/MACCE,[9,11–12,16–
17,19–20,23] although Leacche et al[22] found that MACE was
significantly worse with HCR in high-risk patients. Our results
are consistent with the findings of previous meta-analyses[13–15];
although Phan et al[13] found a lower rate of MI in the HCR
group, it should be noted that meta-analysis only included 8
studies compared with the 14 in this meta-analysis. In the longer
term (at 18 months) it has been reported that HCR was
significantly favored for MACCE[21]; whereas, although
MACCE was similar at 30 months, the stroke rate was
significantly lower in the HCR group.[23] These findings suggest
that HCR is safe and in the mid-long term may offer significant
benefits compared with conventional CABG.
Ventilation time was shorter in the HCR patients. It has been
reported that shorter extubation time reduces the risk of
ventilator-acquired pneumonia, improves rehabilitation, and
decreases ICU stays.[29] This is consistent with the trend toward a
shorter ICU time that was observed in the HCR group. The
shorter ventilation timemay also be due to the minimally invasive
nature of the LIMA to LAD surgery.[6]4.1. Limitations
Only one of the 14 included studies in this meta-analysis was a
randomized trial.[20] The remainder were nonrandomized. This
[7] Papakonstantinou NA, Baikoussis NG, Dedeilias P, et al. Cardiac
Reynolds and King Medicine (2018) 97:33 www.md-journal.comintroduces the possibility of selection bias. In addition, several of
the funnel plots were asymmetric suggesting the added possibility
of publication bias in some measurements. This meta-analysis
is also constrained by the small sample size in several of
the included studies with 5 studies containing <100
patients.[11–12,17–19]
The approach used to carry out the conventional CABG varied
among surgeons with some using off pump,[9,11–12,17,21,23,25]
some on-pump,[18,22] and others leaving it to the surgeon’s
preference.[10,16,19–20] It is known that in the short term (<30
days) off pumpmay have better clinical outcomes[30]; however, in
the longer term (5 years) on-pump is significantly favored in terms
of mortality.[31]
There were also differences in the timing of the PCI after the
LIMA to LAD surgery among the different studies. In most cases
the surgery and PCI were carried out on the same day; however,
in 2 cases the PCI was carried out after 21hours[20] or 48
hours.[19]
Finally, there were differences in the approach used to perform
the LIMA to LAD surgery. This included the use of robotics[17] or
endoscopic approaches[9–10,20] and the precise location of the
minimally invasive incision (e.g., ministernotomy[16] vs anterior
lateral small thoracotomy).[12]5. Conclusions
In the short term, HCR is as safe as conventional CABG and may
offer certain benefits such as a lower requirement for blood
transfusion and shorter hospital stays. However, HCR is more
expensive than conventional CABG.Author contributions
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